As part of our long-term expansion plans, Altruist Biologics aims to support clients from lab to commercialization, reduce the overall cost of essential biopharmaceutical products, and accelerate the delivery of high-quality, affordable medicines to patients worldwide. With the addition of our new Hangzhou facility, we now hold a total manufacturing capacity of 140,000 liters across our portfolio. All of our sites meet GMP requirements of worldwide health agencies, including the FDA, EMA, and NMPA.
Suzhou,China
Our Suzhou site consists of a cell and gene therapy plant and a multi-product antibody manufacturing plant.
- It holds one of the largest commercialized antibody manufacturing capacities in China at 60,000 liters, and is equipped with international standard process equipment, analytical instruments, HVAC systems, and an online monitoring system.
Hangzhou,China
Employing advanced manufacturing and quality systems, our new Hangzhou facility boasts four 20,000L bioreactors, the first of its size and largest in China, for a total 80,000-liter capacity.
- Future expansion plans at the site include a standalone bioconjugation facility for commercial manufacturing of antibody-drug conjugates (ADCs).
- The Hangzhou site will have a total capacity of 172,000 liters when it becomes fully completed in 2026.
Copyright@Altruist Biologics
Subscribe to our newsletter
Incorrect Email Format
Subscribe to our newsletter
Incorrect Email Format